Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
ADMA Biologics Inc (ADMA) had Consolidated Net Income/Loss of $36.43M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$134.22M |
|
$36.43M |
|
$58.60M |
|
$75.63M |
|
$83.21M |
|
$51.01M |
|
$-3.50M |
|
$47.52M |
|
$47.52M |
|
$36.43M |
|
$36.43M |
|
|
Consolidated Net Income/Loss |
$36.43M |
$36.43M |
|
$51.01M |
|
$53.17M |
|
238.60M |
|
244.66M |
|
$0.15 |
|
$0.15 |
|
| Balance Sheet Financials | |
$402.65M |
|
$69.51M |
|
$166.03M |
|
$568.69M |
|
$56.49M |
|
$79.48M |
|
$81.01M |
|
$137.50M |
|
$431.19M |
|
$427.17M |
|
$431.19M |
|
238.33M |
|
| Cash Flow Statement Financials | |
$14.76M |
|
$-21.61M |
|
$-34.90M |
|
$103.15M |
|
$61.38M |
|
$-41.76M |
|
$14.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.13 |
|
-- |
|
-- |
|
0.16 |
|
0.19 |
|
56.34% |
|
38.01% |
|
38.01% |
|
-- |
|
35.40% |
|
27.14% |
|
$-6.73M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
0.30 |
|
0.97 |
|
92.31 |
|
8.45% |
|
8.53% |
|
6.41% |
|
7.13% |
|
$1.81 |
|
$-0.03 |
|
$0.06 |
|